Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger coho...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Biol Ther
Main Authors: Pizzuti, Laura, Sergi, Domenico, Sperduti, Isabella, Lauro, Luigi Di, Mazzotta, Marco, Botti, Claudio, Izzo, Fiorentino, Marchetti, Luca, Tomao, Silverio, Marchetti, Paolo, Natoli, Clara, Grassadonia, Antonino, Gamucci, Teresa, Mentuccia, Lucia, Magnolfi, Emanuela, Vaccaro, Angela, Cassano, Alessandra, Rossi, Ernesto, Botticelli, Andrea, Sini, Valentina, Sarobba, Maria G, Fabbri, Maria Agnese, Moscetti, Luca, Astone, Antonio, Michelotti, Andrea, De Angelis, Claudia, Bertolini, Ilaria, Angelini, Francesco, Ciliberto, Gennaro, Maugeri-Saccà, Marcello, Giordano, Antonio, Barba, Maddalena, Vici, Patrizia
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2018
Teme:
Research Papers
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5902232/
https://ncbi.nlm.nih.gov/pubmed/29336662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2017.1416938
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki